Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
06/13/2012 | 02:52pm CET
   By Victoria Stilwell 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
11/22 MERCK AND : BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted..
11/22 ROCHE : Lung cancer data gives Roches Tecentriq a boost
11/22 MERCK AND : Startup wants to repurpose an old drug Startup wants to bring back V..
11/21 THE LATEST : Startup could bring back Vioxx for hemophilia
11/21 APNEWSBREAK : Startup could bring back Vioxx for hemophilia
11/21 MERCK AND : Technology, retail send stocks higher
11/21 MERCK AND : Startup wants to bring back Vioxx for hemophilia joint pain
11/17 MERCK AND : ACC, John L. Weinberg Center for Corporate Governance Interview Merc..
11/16 MERCK AND : StayWells Krames On FHIR App Listed in App Orchard
11/16 BERGENBIO : to present at Jefferies 2017 London Healthcare Conference
More news
News from SeekingAlpha
11/22 REPORT : UPS license lets it get into pharma supply chain
11/22 GILEAD : Buying New Growth
11/21 YOUR DAILY PHARMA SCOOP : Roche Rallies, Alnylam Granted BTD, Celsion Soars
11/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 21, 2017
11/20 Roche Rocks On With More Good News
Financials ($)
Sales 2017 40 238 M
EBIT 2017 13 727 M
Net income 2017 5 247 M
Debt 2017 12 094 M
Yield 2017 3,48%
P/E ratio 2017 26,23
P/E ratio 2018 16,95
EV / Sales 2017 3,98x
EV / Sales 2018 3,90x
Capitalization 148 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 65,3 $
Spread / Average Target 20%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-6.23%148 014
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 090
ROCHE HOLDING LTD.-1.55%212 522
PFIZER8.90%211 844
AMGEN16.27%123 289